clinical trial · NCT04531982
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
SchizophreniaPimavanserinPlacebo
brief summary
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of negative symptoms of schizophrenia
started
Aug 5, 2020
primary completion
Jan 25, 2024
completion
Feb 19, 2024
last updated
Aug 22, 2025
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol